LV15082A - Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients - Google Patents
Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients Download PDFInfo
- Publication number
- LV15082A LV15082A LVP-15-90A LV150090A LV15082A LV 15082 A LV15082 A LV 15082A LV 150090 A LV150090 A LV 150090A LV 15082 A LV15082 A LV 15082A
- Authority
- LV
- Latvia
- Prior art keywords
- skin
- cream
- patients
- metabolic syndrome
- composition
- Prior art date
Links
- 239000006071 cream Substances 0.000 title claims abstract description 102
- 150000002632 lipids Chemical class 0.000 title claims abstract description 39
- 230000004888 barrier function Effects 0.000 title claims abstract description 29
- 230000001815 facial effect Effects 0.000 title claims abstract description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims description 32
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims description 32
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 45
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims abstract description 21
- 229940032094 squalane Drugs 0.000 claims abstract description 21
- RJFAYQIBOAGBLC-BYPYZUCNSA-N Selenium-L-methionine Chemical compound C[Se]CC[C@H](N)C(O)=O RJFAYQIBOAGBLC-BYPYZUCNSA-N 0.000 claims abstract description 17
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 9
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940042585 tocopherol acetate Drugs 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 19
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 18
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 18
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 13
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 10
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 10
- 235000013772 propylene glycol Nutrition 0.000 claims description 10
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 9
- 229960000541 cetyl alcohol Drugs 0.000 claims description 9
- 239000008213 purified water Substances 0.000 claims description 9
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 8
- 239000003871 white petrolatum Substances 0.000 claims description 8
- 229940057917 medium chain triglycerides Drugs 0.000 claims description 6
- 150000003626 triacylglycerols Chemical class 0.000 claims description 5
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 230000003716 rejuvenation Effects 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000000203 mixture Substances 0.000 abstract description 49
- 210000003491 skin Anatomy 0.000 description 87
- 230000000694 effects Effects 0.000 description 29
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 20
- 238000000034 method Methods 0.000 description 16
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 14
- 239000003925 fat Substances 0.000 description 12
- 235000019197 fats Nutrition 0.000 description 12
- 239000000126 substance Substances 0.000 description 12
- RJFAYQIBOAGBLC-UHFFFAOYSA-N Selenomethionine Natural products C[Se]CCC(N)C(O)=O RJFAYQIBOAGBLC-UHFFFAOYSA-N 0.000 description 11
- 230000002209 hydrophobic effect Effects 0.000 description 11
- 230000002829 reductive effect Effects 0.000 description 11
- 229940099259 vaseline Drugs 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 206010040844 Skin exfoliation Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 208000012641 Pigmentation disease Diseases 0.000 description 8
- 229930003427 Vitamin E Natural products 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 235000019198 oils Nutrition 0.000 description 8
- 208000003154 papilloma Diseases 0.000 description 8
- 230000019612 pigmentation Effects 0.000 description 8
- 229960002718 selenomethionine Drugs 0.000 description 8
- 235000019165 vitamin E Nutrition 0.000 description 8
- 239000011709 vitamin E Substances 0.000 description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- 239000003963 antioxidant agent Substances 0.000 description 7
- 239000002585 base Substances 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001821 langerhans cell Anatomy 0.000 description 7
- 229960004063 propylene glycol Drugs 0.000 description 7
- 229910052711 selenium Inorganic materials 0.000 description 7
- 239000011669 selenium Substances 0.000 description 7
- 230000008719 thickening Effects 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 7
- 229940046009 vitamin E Drugs 0.000 description 7
- 206010013786 Dry skin Diseases 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002537 cosmetic Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000003995 emulsifying agent Substances 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000036572 transepidermal water loss Effects 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 206010039792 Seborrhoea Diseases 0.000 description 5
- 229940087168 alpha tocopherol Drugs 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 230000037336 dry skin Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 229960000984 tocofersolan Drugs 0.000 description 5
- 235000004835 α-tocopherol Nutrition 0.000 description 5
- 239000002076 α-tocopherol Substances 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- 229940106189 ceramide Drugs 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000004519 grease Substances 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 229930003799 tocopherol Natural products 0.000 description 4
- 239000011732 tocopherol Substances 0.000 description 4
- 235000010384 tocopherol Nutrition 0.000 description 4
- 229960001295 tocopherol Drugs 0.000 description 4
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 206010012438 Dermatitis atopic Diseases 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004909 Moisturizer Substances 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- 239000004902 Softening Agent Substances 0.000 description 3
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 150000001783 ceramides Chemical class 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229960003511 macrogol Drugs 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 230000001333 moisturizer Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004224 protection Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 230000008591 skin barrier function Effects 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 230000036620 skin dryness Effects 0.000 description 3
- 230000037067 skin hydration Effects 0.000 description 3
- 229940031439 squalene Drugs 0.000 description 3
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004895 Lipoproteins Human genes 0.000 description 2
- 108090001030 Lipoproteins Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000035987 intoxication Effects 0.000 description 2
- 231100000566 intoxication Toxicity 0.000 description 2
- 206010024217 lentigo Diseases 0.000 description 2
- 239000002960 lipid emulsion Substances 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000003711 photoprotective effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 229910000338 selenium disulfide Inorganic materials 0.000 description 2
- JNMWHTHYDQTDQZ-UHFFFAOYSA-N selenium sulfide Chemical compound S=[Se]=S JNMWHTHYDQTDQZ-UHFFFAOYSA-N 0.000 description 2
- 229960005265 selenium sulfide Drugs 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 230000037377 skin turgor Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010064503 Excessive skin Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 206010062049 Lymphocytic infiltration Diseases 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000031709 Skin Manifestations Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037365 barrier function of the epidermis Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 125000001895 carotenoid group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 239000007957 coemulsifier Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000003595 dermal dendritic cell Anatomy 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 101150022035 exog gene Proteins 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003084 food emulsifier Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- -1 lipid lipid Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 1
- 229960003987 melatonin Drugs 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000005375 photometry Methods 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 230000001012 protector Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000013568 regulation of keratinocyte differentiation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000004492 retinoid derivatives Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 150000003342 selenium Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 230000004215 skin function Effects 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 230000036548 skin texture Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/368—Carboxylic acids; Salts or anhydrides thereof with carboxyl groups directly bound to carbon atoms of aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
IZGUDROJUMA APRAKSTSDESCRIPTION OF THE INVENTION
Izgudrojums attiecas uz medicīnu, ir saistīts ar ģimenes medicīnu (ģimenes ārstu praksi), terapiju, endokrinoloģiju, gerontoloģiju, dermatoloģiju un kosmetoloģiju, kā arī risina sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanas problēmas pacientiem ar metabolisko sindromu.The invention relates to medicine, is related to family medicine (family practitioners), therapy, endocrinology, gerontology, dermatology and cosmetology, as well as solves the problems of regeneration of epidermal lipid barrier in the skin of the face, neck and décolleté in patients with metabolic syndrome.
TEHNIKAS LĪMENISTECHNICAL LEVEL
Metaboliskais sindroms (MS) - izmaiņu komplekss, kas saistīts ar vielmaiņas traucējumiem, kura gadījumā attīstās nejutība pret insulīnu, tiek traucēta glikozes uzņemšana šūnās. Metaboliskajam sindromam seko dažādu saslimšanu komplekss: hipertonija, aptaukošanās, sirds išēmiskā slimība, 2. tipa cukura diabēts. Metaboliskā sindroma attīstību raksturo vidukļa apkārtmēra palielināšanās: vīriešiem - vairāk par 102 cm, sievietēm - vairāk par 88 cm. Arteriālā asinsspiediena līmenis -135/85 mmHg. Asinīs kostatē augstu lipīdu peroksidācijas produktu saturu. Oksidanti sāk aktivēt šūnu reakcijas, kas sagrauj olbaltumvielas, lipīdus, DNS. Tiek traucēta ādas baijerfunkcija un tā intensīvāk zaudē mitrumu, kļūst sausa, kas izraisa pārmērīgu ādas zvīņošanos, ādas ragveida slāņa sabiezējumu, piešķir ādai pelēcīgu nokrāsu, sekmē dažādu ādas saslimšanu attīstību: seboreja, atrofiskais dermatīts, psoriāze, ekzēma u.c. saslimšanas [ 1 ].Metabolic Syndrome (MS) - a complex of changes associated with metabolic disorders in which insulin resistance develops, impairing the uptake of glucose in cells. Metabolic syndrome is followed by a complex of different diseases: hypertension, obesity, ischemic heart disease, type 2 diabetes. The development of metabolic syndrome is characterized by an increase in the waist circumference: more than 102 cm for men and more than 88 cm for women. Arterial blood pressure -135/85 mmHg. High levels of lipid peroxidation products in the blood. Oxidants start to activate cellular reactions that destroy proteins, lipids, DNA. The skin's Bavarian function is disturbed and it loses its moisture more intensively, it becomes dry, causing excessive skin flaking, thickening of the skin's horny layer, giving the skin a gray tinge, contributing to the development of various skin diseases: seborrhea, atrophic dermatitis, psoriasis, eczema, etc. diseases [1].
Cilvēka ķermeņa āda ir sarežģīta bioloģiska audu sistēma, kum veido epiderma, derma un zemādas tauku šūnaūdi. Epidermas bazālajā slānī atrodas melanocīti un Langerhansa šūnas, kas izvietotas uz bazālās membrānas. Epidermas pamatslānī atrodas protoplazmas šķiedras, granulveida slāni veido šūnas ar keratohialīna kompleksiem. Derma - ādas savienojošā daļa, galvenais ādas apjoms. Derma ar bazālo membrānu norobežota no epidermas [2].The human body skin is a complex biological tissue system, composed of epidermis, dermis and subcutaneous fat cells. The epidermal basal layer contains melanocytes and Langerhans cells located on the basal membrane. In the epidermal base layer, protoplasm fibers are present, the granular layer forms cells with keratohialin complexes. Derma - the connecting part of the skin, the main skin volume. Derma with basal membrane delimited from the epidermis [2].
Epidermas ārējo daļu klāj raga slānis, uz kura izveidota ūdens-lipīdu mantija ar vāji skābu vidi - skābuma līmenis 4,5-5,5 pH. Šāds skābuma līmenis rada baktericīdu iedarbību un sekmē lipīdu sintēzi. Ādas skābes īpašības saistītas ar sviedriem un ādas taukiem. Daudzie uz ādas nokļūstošie mikrobi iet bojā 20-30 minūšu laikā [3]. Ūdens-lipīdu mantija veido epidermālo baijeru, kas sastāv no ragveida šūnām - zvīņām, kuras tiek sauktas par komeocītiem, starp kuriem izvietoti epidermālie starpšūnu lipīdi - keramīdi. Keramīdi savieno komeocītus necaurejamā, 2 viengabalainā epidermālā barjerā. Keramīdu molekulām ir polāra struktūra, jo tām ir hidrofilas galvas (dod priekšroku ūdenim) un lipofilas astes (dod priekšroku taukiem). Epidermālā lipīdu barjera neļauj iekļūt ādā kaitīgām vielām, iesaistās dermas ūdens hemostāzes regulēšanā. Lipīdu barjera sastāv no holesterīna, keramīdiem, nepiesātinātām taukskābēm (Omega-3, Omega-6). Nepiesātinātajām taukskābēm Omega-3, Omega-6 piemīt pretiekaisuma iedarbība, tās stimulē Langerhansa šūnas un nostiprina epidermālo lipīdu barjeru [4]. Brīvās taukskābes izvietotas lipīdu slānī, apkārt keramīdiem, tās sekmē ādas ūdens necaurlaidības funkciju, veido ūdens-eļļas emulsiju. Ja lipīdu barjera tiek traucēta, tad ādā iekļūst mikroorganismi, ķīmiskie un citi eksogēnie agresīvie faktori. Ādai ir imūno šūnu sistēma, galvenā loma ir Langerhansa šūnām (2-5 % šūnu epidermas). Langerhansa šūnas piedalās baktēriju iznīcināšanā un ierosina imūno atbildi, kurā piedalās dermālās dendritu šūnas, epidermālie makrofagi u.c. Ādas novecošanās saistīta ar imūnās sistēmas stāvokli [5]. Pēc 25 gadu vecuma organismā sāk darboties dabiskas novecošanās mehānisms: samazinās ādas makrofagu daudzums, oksidanti sāk aktivēt šūnu reakcijas, radot olbaltumvielu, lipīdu un DNS traucējumus. īpaši aktīvi ādas paātrinātas, patoloģiskas novecošanās process sākas slimniekiem ar metabolisko sindromu (MS). Zināms, ka metabolisko sindromu pavada latents iekaisums, kas izraisa peroksidācijas procesu aktivizāciju. Lipīdu peroksidācijas produktu uzkrāšanās, lipoproteīnu un lipīdu slāņa lipīdu oksidatīvie bojājumi izpaužas kā ādas struktūras komponentu morfoloģiskās izmaiņas [6]. Aizsardzības sistēma, ko veido antioksidanti, pacientiem ar metabolisko sindromu ir novājināta un/vai neefektīvā. Metaboliskā sindroma gadījumā rodas oksidatīvais stress: tiek traucēta keratinocītu veidošanās, novērojams transepidermālā ūdens pastiprināts zudums, ādas sausums, plaisas un erozijas. Izmaiņas izraisa ādas mikrofloras disbalansu un sēnīšu skaita pieaugumu, papilomu rašanos. Ādas epidermālās lipīdu barjeras atjaunošana pacientiem ar metabolisko sindromu ir īpaši aktuāls uzdevums [7]. 1. tabula - ādas epidermālās lipīdu barjeras traucējumu analīze un to noteikšanas metodes. 3 1. tabula Ādas epidermālās lipīdu barjeras traucējumu analīze un to noteikšanas metodes Traucējumu klīniskās izpausmes Transepidermālā ūdens zuduma paātrinājums (tevametrija) un ūdens saturs epidermas raga slānī (korneometrija). Ādas sausums, lobīšanās, plaisas, raga slāņa sabiezēšana (hiperkeratoze). Ādas skābju-sārmu līdzsvara izmaiņas, pH (pH-metrijas sensors). Papilomas, ādas inficēšanās, lipīdu sintēzes traucējumi. Ādas reljefa un morfoloģiskais stāvoklis (dermatoskopija, mikrofotogrāfija). Ādas turgors, mikroreļjefs, papilomas, elastības samazināšanās, elastoze. Pigmentācija un lobīšanās (siaskopija, meksametrija). Lentigo orgāni un/vai pigmentācijas neviendabīgums (dispigmentācija). Ādas imunitāte (gaismas mikroskopija, imūnhistoķīmija). Imūnkompetentās Langerhansa šūnas, Birbeka granulas, baktēriju un/vai vīrusu, papilomu iekļūšana ādā. Ādas dažādu zonu taukainība (sebumetrija). Āda sausa, taukaina, normāla, kombinēta. Epidermas proliferācijas ātrums (mikrofotografešana). Komeocītu izmēri, lielās komeocītu šūnas ādas dehidratācijas gadījumā. LV 15082 Ādas epidermālās lipīdu barjeras traucējumu analīzi veic ar dermatoskopijas starpniecību (ādas pH, mitruma/sausuma, taukainības novērtēšana) un siaskopijas starpniecību (dispigmentācijas izvērtējums un mikroreljefa izpēte). Transepidermālā ūdens zuduma mērīšanai izmanto sensoru Tewameter® TM 300, Courage + Khazaka electronic GmbH, Vācija. Siaskopijas veikšanai izmanto siaskopu MoleView SIAscope V Handset, Astron, Lielbritānija. Dermatoskopijas veikšanai izmanto dermatoskopu HEINE alpha + Heine Optotechnic, Vācija. Tos izmantojot, analizē uz datoru pārsūtītos rādītājus, vienlaikus veicot vairāku epidermālās lipīdu barjeras stāvokļa atspoguļojošo raksturlielu analīzi [8-11]: • Korneometrija (ādas mitrums, ūdens saturs epidermas raga slānī), izmanto ar dermatoskopa palīdzību. Komeometrijas princips pamatojas uz dielektriskās vides elektriskās kapacitātes mērīšanu. Jebkādas dielektriskās konstantes izmaiņas, kas saistītas ar ūdens satura svārstībām ādas virsējos slāņos, izraisa mērīšanas sistēmas kapacitatīvo raksturlielumu izmaiņas. Mitrināšanu vērtē pēc skalas. Par pamatu tiek ņemta ūdens dielektriskā kapacitāte - 81, izšķir 4-6 ādas mitrinājuma pakāpes (ļoti augsta mitrinājuma pakāpe - 45,0-99,9; augsta, normāla - 4 35,1-40,0; pazemināta, zema-20,1-29,9; atūdeņota - zemāka par 20,0). • Transepidermālā ūdens zuduma mērīšana, mērījums ūdens iztvaikošanai no ādas virsmas, kas pamatojas uz difūzijas principu atvērtā kamerā. Metode pamatojas uz ūdens parciālā spiediena mērīšanu slēgtā kamerā ar vienu mitruma sensoru. Noteiktā laika periodā mēra parciālā spiediena pieaugumu kamerā. • Skābes-bāzes līdzsvars, pH-metrija. pH-metrijas sensorā izmanto ļoti precīzu stikla elektrodu. • Sebumetrija, sebumetrijas metodi izmanto, lai dažādās zonās noteiktu ādas taukainību. Metodes pamatā fotometrijas princips. Lieto polimēra plēvi, kura ir selektīvs lipīdu absorbents, kuru pirms un pēc raidītāja aplikācijas uz ādas virsmas ievieto fotometrā. Mērīšanas rezultāti tiek izteikti mkg/cm. Sebumetrijas rādītāji nav atkarīgi no ādas mitruma. Taukainības sensors (sponžs) sastāv no trijiem komponentiem, viens no tiem ir papīrs - matēts, jutigs pret tauku sastāvdaļām, kurš reaģē tikai uz sebumu (ādas taukiem), absorbē to, mikroprocesors apstrādā iegūtās krāsas izmaiņas, nosakot ādas tipu: sausa, normāla, taukaina vai kombinēta. • Meksametrija (dažādu ādas pigmentu satura novērtējums), ļauj izmērīt melatonīna pigmenta daudzumu ādā un eritēmas pakāpi. Mērīšanas princips pamatots uz to, ka āda dažādās spektra zonās uzsūc dažāda garuma gaismas viļņus. Meksametrijas metode ir īpaši lietderīga, veicot ultravioletā bojājuma izraisītu alerģijas vai iekaisuma reakcijas skaitlisko izvērtēšanu. • Mikroreljefa izpēte ar mikrofotografēšanu - mūsdienīgas ciparu aparatūras izmantošana ādas virsmas reljefa un mikrostruktūras izvērtēšanai (krunkainība, gludums, raupjums) ar sekojošu attēlu saglabāšanu un iespēju salīdzināt, kā arī analizēt mērījumus ārstēšanas kursa laikā. Ādas lobīšanās galvenokārt atkarīga no epidermas proliferācijas ātruma, kā arī no ūdems līdzsvara. Normai atbilstoši aizejošie komeocīti ir apmēram vienāda, neliela izmēra. Apjomīgais lielo šūnu skaits liecina par ādas bojājumu un dehidratizāciju.The outer part of the epidermis is covered by a layer of horn, on which a water-lipid mantle with a weak acidic environment is formed - a pH of 4.5-5.5. This level of acidity produces bactericidal activity and promotes lipid synthesis. Skin acid properties are associated with sweat and skin fat. Many microbes that get on the skin die in 20-30 minutes [3]. A water-lipid mantle forms an epidermal bay, consisting of horny cells - scales, called comaocytes, among which are epidermal intercellular lipids - ceramides. The ceramides bind the comocytes in an impermeable, 2-piece, epidermal barrier. Ceramic molecules have a polar structure because they have hydrophilic heads (prefer water) and lipophilic tails (prefer fats). The epidermal lipid barrier prevents the penetration of harmful substances into the skin, engages in the regulation of dermal water hemostasis. The lipid barrier consists of cholesterol, ceramides, unsaturated fatty acids (Omega-3, Omega-6). Omega-3 unsaturated fatty acids have anti-inflammatory effects, stimulate Langerhans cells and strengthen the epidermal lipid barrier [4]. Free fatty acids are placed in the lipid layer around the ceramides, they contribute to the water tightness of the skin, form a water-oil emulsion. If the lipid barrier is disturbed, microorganisms, chemical and other exogenous aggressive factors enter the skin. The skin has an immune cell system, with Langerhans cells playing a key role (2-5% cellular epidermis). Langerhans cells are involved in the destruction of bacteria and initiate an immune response involving dermal dendritic cells, epidermal macrophages, etc. Skin aging is associated with the state of the immune system [5]. After the age of 25, the body has a mechanism of natural aging: the amount of macrophages in the skin is reduced, oxidants start to activate cellular reactions, causing protein, lipid and DNA disturbances. particularly active skin accelerated, pathological aging process begins in patients with metabolic syndrome (MS). It is known that metabolic syndrome is accompanied by latent inflammation that causes the activation of peroxidation processes. Accumulation of lipid peroxidation products, lipoprotein and lipid lipid oxidative lesions are manifested as morphological changes in skin structure components [6]. The antioxidant protective system in patients with metabolic syndrome is weakened and / or ineffective. In the case of metabolic syndrome, oxidative stress occurs: keratinocyte formation is impaired, increased transepidermal water loss, dry skin, cracks and erosions. Changes cause imbalances in the microflora of the skin and an increase in the number of fungi, papillomas. Reconstruction of the epidermal lipid barrier in patients with metabolic syndrome is a particular challenge [7]. Table 1 - Analysis of skin epidermal lipid barrier disorders and methods for their detection. 3 Table 1 Analysis of skin epidermal lipid barrier disorders and methods for their detection Clinical manifestations of disturbances Acceleration of transepidermal water loss (caramel) and water content in the epidermal horn layer (corneometry). Skin dryness, peeling, cracks, thickening of the horn layer (hyperkeratosis). Changes in skin acid-alkali balance, pH (pH-metric sensor). Papilloma, skin infection, lipid synthesis disorders. Skin relief and morphological condition (dermatoscopy, microphotography). Skin turgor, micro-oil, papillomas, decreased elasticity, elastosis. Pigmentation and exfoliation (siascopy, mexameters). Lentigo organs and / or pigmentation heterogeneity (dispigmentation). Skin immunity (light microscopy, immunohistochemistry). Immune-competent Langerhans cells, Birbeka pellets, bacteria and / or viruses, papillomas entering the skin. Oils of different areas of the skin (sebumetry). Skin dry, oily, normal, combined. Epidermal proliferation rate (microphotography). Dimensions of comocytes, large comocytes cells in case of skin dehydration. EN 15082 Analysis of skin epidermal lipid barrier disorders is performed through dermatoscopy (skin pH, moisture / drought, grease evaluation) and siachopy (dispigmentation assessment and microrelief examination). Tewameter® TM 300, Courage + Khazaka electronic GmbH, Germany is used to measure transepidermal water loss. The Siaopolis MoleView SIAscope V Handset, Astron, United Kingdom is used to perform the Siachopia. Dermatoscope HEINE alpha + Heine Optotechnic, Germany, is used for dermatoscopy. They are used to analyze the data transmitted to the computer while performing a multi-epidermal lipid barrier characteristic analysis [8-11]: • Corneometry (skin moisture, water content in the epidermal horn layer) is used with the help of the dermatoscope. The principle of comometry is based on the measurement of the electrical capacity of the dielectric environment. Any change in the dielectric constant associated with fluctuations in water content in the upper layers of the skin results in changes in the capacitive characteristics of the measuring system. Moisture is measured on a scale. The basis is water dielectric capacity - 81, distinguishes 4-6 degrees of skin hydration (very high degree of humidity - 45.0-99.9; high, normal - 4 35.1-40.0; lowered, low-20, 1-29.9, dehydrated - below 20.0). • Measurement of transepidermal water loss, measurement of water evaporation from a skin surface based on the diffusion principle in an open chamber. The method is based on measuring partial water pressure in a closed chamber with one humidity sensor. Over time, the partial pressure increase in the chamber is measured. • Acid-base balance, pH-metric. A highly accurate glass electrode is used in the pH-meter sensor. • Sebumetria, a method of sebumetry, is used to detect skin fat in different areas. The method is based on the principle of photometry. A polymer film is used, which is a selective lipid absorbent which is placed in the photometer before and after application of the transmitter on the skin surface. Measurement results are expressed in mkg / cm. Sebumetry rates do not depend on skin moisture. The grease sensor (spongy) consists of three components, one of which is paper - matte, sensitive to fat components, which reacts only to sebum (skin fat), absorbs it, the microprocessor processes the resulting color change, determining the skin type: dry, normal, oily or combined. • Mexameters (assessment of the content of various skin pigments) allows to measure the amount of melatonin pigment in the skin and the degree of erythema. The principle of measurement is based on the fact that the skin absorbs light waves of different lengths in different spectral zones. The Mexometric method is particularly useful for quantifying allergic or inflammatory reactions caused by ultraviolet damage. • Microprint research with microphotography - use of modern digital equipment for skin surface relief and microstructure (wrinkling, smoothness, roughness) with subsequent image retention and comparison, as well as analysis of measurements during the course of treatment. Skin peeling depends mainly on the rate of epidermal proliferation as well as on the balance of the water. Normally, outgoing comocytes are about the same, small in size. The large number of large cells indicates damage to the skin and dehydration.
Zināmas kosmētiskas kompozīcijas ādas sausuma profilaksei un ārstēšanai ultravioleto (UV) bojājumu gadījumā. Zināmās kompozīcijas satur augu ekstraktus un komponentus kombinācijā ar dažādām eļļām [12-14]. Zināms, ka UV prooksidatāvo iedarbību iespējams koriģēt ar vitamīhiem-antioksidantiem [15-21]. Zināma retinoīdu lietošana UV bojājumu novēršanai [22]. Zināms krēms ar selēnmetionīnu vietējai 5 LV 15082 lietošanai insolācijas laikā, lai aizsargātos no ādas vēža [23]. Zināma mitrinošu krēmu lietošana, kuros ir liels keramīdu pārsvars, kuri paredzēti lietošanai bērniem ar atopisko dermatītu [24],Known cosmetic compositions for the prevention and treatment of skin dryness in ultraviolet (UV) lesions. Known compositions contain plant extracts and components in combination with various oils [12-14]. It is known that the effect of UV proxy can be corrected with vitamin-antioxidants [15-21]. Known use of retinoids to prevent UV damage [22]. Known cream with selenomethionine for topical 5 EN 15082 use during insolation to protect against skin cancer [23]. Known use of moisturizing creams with high ceramics predominance for children with atopic dermatitis [24],
Zināma mitrinošu līdzekļu lietošana sausas ādas ārstēšanai [25-26]. Zināma krēmu lietošana, kuros tokoferols ir kā antioksidants aizsardzībai no ādas UV bojājuma [27].Use of moisturizing agents to treat dry skin [25-26]. Known use of cream in which tocopherol is an antioxidant to protect the skin from UV damage [27].
Zināmie mitrinošie un mīkstinošie līdzekļi, kuri atvieglo ādas sausuma simptomus, ādu uzlabo mitrinot, bet neatjauno, kā ari neatrisina epidermālās lipīdu barjeras atjaunošanas problēmu pacientiem ar metabolisko sindromu.Known moisturizing and softening agents that relieve skin dryness, improve skin by moisturizing, but do not restore, as well as solve the problem of epidermal lipid restoration in patients with metabolic syndrome.
Zināms vazelīns [28], kas tiek lietots, lai īslaicīgi aizstātu bojāto ādas barjeru.Known Vaseline [28], which is used to temporarily replace the damaged skin barrier.
Vazelīns un līdzekļi, kas bāzējas uz to, tiek izmantoti pēc medicīniskām un kosmētiskām procedūrām, kurās notiek raga slāņa noņemšana, tādām kā ādas slīpēšana ar lāzeru, dermabrāzija (mehāniska epidermas noņemšana), pīlings.Vaseline and the products based on it are used for medical and cosmetic procedures in which the horn layer is removed, such as laser grinding of the skin, dermabrasion (mechanical removal of the epidermis), peeling.
Vazelīna trūkums ir slikta uzsūkšanās ādā, jo āda tiek pārklāta ar taukainu slāni, kas sarežģī tā lietošanu. Vazelīnam piemīt spēcīgs okluzīvs efekts (mitruma izgarošanas bloķēšana), kas noved pie ādas caurlaidības traucējumiem un blaknēm. Vazelīnu rekomendē lietot tikai akūta epidermālās baņeras bojājuma gadījumā, kad nepieciešams novērst īpaši aktīvu ādas šūnu reakciju, kuras pēkšņi zaudējušas ārējo aizsardzību, kā ari tajās situācijās, kad āda pati nav spējīga formēt pilnvērtīgu barjeru. Pārējos gadījumos bloķēt ūdens iztvaikošanu caur bojāto raga slāni nerekomendē.Vaseline deficiency is poor absorption in the skin as the skin is covered with a greasy layer that complicates its use. Vaseline has a strong occlusive effect (moisture vapor blocking), leading to skin permeability disorders and side effects. Vaseline is recommended to be used only in cases of acute epidermal lesion injury, when it is necessary to prevent a particularly active skin cell reaction that has suddenly lost its external protection, as well as in situations where the skin itself is unable to form a complete barrier. In other cases blocking water evaporation through the damaged horn layer is not recommended.
Zināma tauku emulsija, ar kuru vienlaikus iespējama ādas mitrināšana un barošana [29]. Zināmā tauku emulsija neveic aizsargājošu iedarbību pret ādas novecošanās procesiem, kurus izraisījuši ādas brivo radikāļu bojājumi pacientiem ar metabolisko sindromu.A known fat emulsion that can simultaneously moisturize and nourish the skin [29]. A known fat emulsion does not have a protective effect on skin aging processes caused by lesions of the skin's radicals in patients with metabolic syndrome.
Zināms krēms ar selēnu un E vitamīnu [30], kas ir augsti dispersa rafinētas ūdeles eļļas emulsija ūdenī stabilizēta ar emulsijas vaskiem. Krēms nenovērš lipīdu barjeras atjaunošanu pacientiem ar metabolisko sindromu. Turklāt, ilgstoši lietojot krēmu ar augstu ūdens saturu, palēninās raga slāņa atjaunošanās, kas nelabvēlīgi ietekmē ādu pacientiem ar metabolisko sindromu [31]. Zināmas dažādas kompozīcijas no augu ekstraktiem ādas barjerās funkcijas stāvokļa uzlabošanai [32-36]. Zināmās kompozīcijas neatjauno lipīdo slāni pacientiem ar metabolisko sindromu.Known cream with selenium and vitamin E [30], a highly dispersed refined mink oil emulsion in water stabilized with emulsion waxes. The cream does not prevent the lipid barrier being restored in patients with metabolic syndrome. In addition, prolonged use of high-water cream slows down the recovery of the horn layer, which has an adverse effect on the skin in patients with metabolic syndrome [31]. Known different compositions from plant extracts to improve the function of the skin barrier [32-36]. Known compositions do not restore the lipid layer in patients with metabolic syndrome.
Nav zināms līdzeklis epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu. 6No remedy for the restoration of the epidermal lipid barrier in patients with metabolic syndrome is known. 6
IZGUDROJUMA IZKLĀSTSDESCRIPTION OF THE INVENTION
Izgudrojuma mērķis un tehniskais rczulāts: izstrādāt krēma sastāvu sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu, kas novērstu brīvo radikāļu radīto bojājumu lipīdu slānim, kuru izraisījis latents iekaisums, piemītošs metaboliskajam sindromam, un atjaunotu lipīdu slāni: • jaunā sastāva komponentu un to sastarpējās attiecības meklēšana, • krēma izgatavošanas tehnoloģijas izstrādāšana, • krēma optimālās formas izstrādāšana.Purpose and Technical Purpose of the Invention: Develop a cream composition for regeneration of the epidermal lipid barrier in the facial skin, neck and décolleté area in patients with metabolic syndrome that would prevent the free radical damage to the lipid layer caused by latent inflammation inherent in metabolic syndrome and restore the lipid layer: • new search for composition components and their interrelation, • development of cream making technology, • development of optimal cream form.
Izvirzīto mērķi sasniedz tādējādi, ka krēms satur selēn-L-metionīnu, α-tokoferola acetātu, skvalānu, metil-4— hidroksibenzoātu, glicerīna monostearātu 60, cetilspirtu, vidēji garo ķēžu trigliceiīdus, balto vazelīnu, makrogola-20-glicerīna monostearātu, 1,2-propāndiolu un attīrītu ūdeni. Pie tam krēms satur selēn-L-metionīnu, α-tokoferola acetātu, skvalānu, metil-4-hidroksibenzoātu, glicerīna monostearātu 60, cetilspirtu, vidēji garo ķēžu triglicerīdus, balto vazelīnu, makrogola-20-glicerīna monostearātu, 1,2-propāndiolu un attīrītu ūdeni šādās komponentu masas attiecībās g (%): selēn-L-metionīns 0,0005-0,0015; α-tokoferola acetāts 0,50-1,50; skvalāns 11,25-18,75; metil-4- hidroksibenzoāts 0,05-0,15; glicerīna monostearāts 60 2,52-4,20; cetilspirts 3,78-6,29; vidēji garo ķēžu triglicerīdi 4,72-7,87; baltais vazelīns 16,05-26,74; makrogols-20-glicerīna monostearāts 4,40-7,34; 1,2-propāndiols 6,29-10,49; attīrīts ūdens līdz 100,0. Krēma sastāvs ir homogēna masa balta krāsa vai balta krasā ar dzeltenīgu nokrāsu, vāji izteiktu un patīkamu aromātu, atbilstošu lietotajai tauku bāzei. Visi krēma komponenti atļauti lietošanai par farmaceitiskiem līdzekļiem.The goal is achieved by the fact that the cream contains selenium-L-methionine, α-tocopherol acetate, squalane, methyl-4-hydroxybenzoate, glycerol monostearate 60, cetyl alcohol, medium chain triglycerides, white petroleum jelly, macrogol-20-glycerol monostearate, 1, 2-propanediol and purified water. In addition, the cream contains selenium-L-methionine, α-tocopherol acetate, squalane, methyl-4-hydroxybenzoate, glycerol monostearate 60, cetyl alcohol, medium chain triglycerides, white petroleum jelly, macrogol-20-glycerin monostearate, 1,2-propanediol and purified water in the following component weight ratios g (%): selenium-L-methionine 0.0005-0.0015; α-tocopherol acetate 0.50-1.50; squalane 11,25-18,75; methyl 4-hydroxybenzoate 0.05-0.15; glycerol monostearate 60 2.52-4.20; cetyl alcohol 3.78-6.29; medium chain triglycerides 4.72-7.87; White Vaseline 16.05-26.74; macrogol-20-glycerol monostearate 4.40-7.34; 1,2-propanediol 6.29-10.49; purified water to 100.0. The cream composition is a homogeneous mass of white or white in color with a yellowish tinge, a weak and pleasant aroma, consistent with the fat base used. All cream components are authorized for pharmaceutical use.
Krēms paredzēts sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu. 7 LV 15082The cream is designed to rejuvenate the epidermal lipid barrier of the face, neck and décolleté patients with metabolic syndrome. 7 LV 15082
Krēma sastāvs satur šādus komponentus:The composition of the cream contains the following components:
Selēn-L-metionīns (Selenomethionine, Se-Met (SEM)) - selēnmetionīna L-enantiomērs, dabīga selēnu saturoša aminoskābe, tā ir nozīmīgs selēna avots.Selenomethionine (Se-Met (SEM)) - L-enantiomer of selenomethionine, a natural selenium-containing amino acid, is an important source of selenium.
Selēnmetionīns veic bioantioksidata funkciju, mijiedarbojas ar vitamīniem, fermentiem, bioloģiskajām membrānām bioloģiskajās sistēmās un organismā kopumā.Selenium methionine performs a bioanthoxidate function, interacts with vitamins, enzymes, biological membranes in biological systems and the body as a whole.
Fermenta sastāvā glutationperoksidāzes neitralizē oksīdus un peroksīdus, pasargā šūnu membrānas no sabrukšanas, veic antihistamīnu iedarbību, stimulē kolagēna, keratīna biosintēzi, piedodot ādai stingrumu un elastību, samazina seborejas izpausmes, aktivizē ādas reģeneratīvos procesus, atjauno epidermas struktūru.Glutathione peroxidase neutralizes oxides and peroxides in enzyme composition, protects cell membranes from collapse, exerts antihistamines, stimulates collagen, keratin biosynthesis, gives skin firmness and elasticity, reduces seborrhea, activates skin regenerative processes, restores skin regenerative processes, restores epidermal structure, restores epidermal structure.
Neorganisko selēnu, selēna disulfīdu (Selenium disulfide) lieto galvas ādas matu zonas seborejas ārstēšanai [37]. Pēc ASV pieņemta standarta drošs selēna saturs (no intoksikācijas viedokļa) pieauguša cilvēka ikdienā uzņemamajā uzturā ir 50-220 mkg, saskaņā ar Ķīnā veiktajiem pētījumien toksiskas izpausmes netika novērotas, uzņemot diennaktī 750 mkg selēna, bet intoksikācijas simptomi novērojami, ja diennakts devu palielina līdz 5000 mkg/diena [38],Inorganic selenium, selenium disulfide (Selenium disulfide) is used to treat scalp hair zones in seborrhea [37]. In the US, the standard safe selenium content (from the point of view of intoxication) is 50-220 mcg in the daily diet of an adult, according to studies conducted in China, there was no evidence of daily exposure to 750 mcg of selenium, while symptoms of intoxication were observed when the daily dose was increased to 5,000. mkg / day [38]
Selēnmetionīns ir hidrofila viela, optimālais selēnmetionīna satura efekts krēma sastāvā 0,0005-0,0015 g. Ja tā saturs mazāks par 0,0005 g, tad krēma antioksidatīvā iedarbība samazinājās, bet, ja tā saturs lielāks par 0,0015 g, tad radās grūtības krēma izgatavošanā, izmainījās krēma konsistence, tas noslāņojās, nebija tik viendabīgs, tas apgrūtināja krēma lietošanu.Selenium methionine is a hydrophilic substance, the optimum effect of selenium methionine in the cream composition is 0.0005-0.0015 g. If its content is less than 0.0005 g, the antioxidant effect of the cream was reduced, but if its content was higher than 0.0015 g, the cream was difficult to make, the consistency of the cream changed, it was stratified, it was not homogeneous, it made it difficult to use the cream.
Skvalāns (Squalane) - karotinoīdu grupas dabiskas izcelsmes ogļūdeņradis, caurspīdīga eļļa bez krāsas un aromāta. Skvalāns nesatur dubultsaites, tāpēc tas ir ķīmiski stabils un var uzglabāties vairāk par 2 gadiem, tas neoksidējas un nekļūst rūgtens. Skvalāns sintezējas tauku dziedzeros, tas ir viens no ādas tauku un ūdens-lipīdu mantijas galvenajiem komponentiem. Saskaņā ar dermatokosmetoloģiju skvalans ir augsti kvalitatīvs emolents (mīkstināšanas aģents). Skvalāns ir nekomedogēns, atšķirībā no triglicerīdiem un ādas tauku slāņa taukskābēm [39-dOJ.Squalane - a naturally occurring hydrocarbon of the carotenoid group, a clear oil free of color and aroma. Squalane does not contain double bonds, so it is chemically stable and can be stored for more than 2 years, it does not oxidize and does not become bitter. Squalane synthesizes in sebaceous glands, one of the main components of skin fat and water-lipid mantle. According to dermatocosmetology, squalene is a high quality emollient (softening agent). Squalane is non-comedogenic, unlike triglycerides and fatty acids in the skin [39-dOJ.
Skvalānu uzklājot uz ādas, tas viegli ieziešas, veidojot aizsargājošu plēvi, kas pasargā no mitruma zuduma, uzlabo ādas elpošanu. Pateicoties dabiskajai radniecībai ar ādu, skvalāns viegli izsūcas cauri epideimai, neatstājot nekādu taukainību, vienlaicīgi ādu padara maigu un zīdainu. Skvalāns ir hidrofoba viela, tas aktīvi iesaistās vielmaiņā, steroīdu bioloģiskajā sintēzē, tam piemīt viegls antibakterials efekts, tas palīdz novērst vecuma plankumu rašanos. Optimālais skvalāna satura efekts krēma sastāvā 11,25—18,75 g. Ja tā saturs mazāks par 11,25 g, tad ādas struktūras mīkstināšanas un 8 atjaunošanas efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 18,75 g, tad. radās grūtības krēma izgatavošanā, samazinājās kompozīcijas stabilitāte, krēms noslāņojās, tika apgrūtināta tā lietošana. E vitamīns, a-tokoferols (Vitamin E, Alpha-tocopherol) - gaiši dzeltens, caurspīdīgs, viskozs šķidrums ar vāju aromātu. Gaismā oksidējas un kļūst tumšs. Tokoferols ir hidrofoba viela, to satur jauno augu zaļās daļas, augu eļļas, tas ir dabiskais antioksidants, kas piedalās brīvo radikāļu inaktivācijā, pasargā šūnu membrānas no sabrukuma, tajā skaitā, arī ultravioletā starojuma gadījumā, piedalās olbaltumvielu sintēzē, samazina seborejas izpausmes, aktivē ādas reģeneratīvos preocesus [41]. E vitamīna iekļaušana krēma sastāvā ļāva sasniegt daudz ātrāku ādas epidermālās lipīdu barjeras atjaunošanu pacientiem ar metabolisko sindromu. Optimālais α-tokoferola (E vitamīna) satura efekts krēma sastāvā 0,50-1,50 g. Ja tā saturs mazāks par 0,50 g, tad efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 1,50 g, tad izmainījās krēma konsistence, tas kļuva ievērojami šķidrāks, tika apgrūtināta tā lietošana.Applying the scalp to the skin, it gently lubricates to form a protective film that protects against moisture loss, improves skin breathing. Thanks to the natural skin contact, squalane easily penetrates through the epidemic, leaving no grease, making the skin soft and silky at the same time. Squalane is a hydrophobic substance that actively engages in metabolism, biological synthesis of steroids, has a mild antibacterial effect and helps prevent age spots. Optimal effect of squalane content in cream composition 11.25-18.75 g. If its content is less than 11.25 g, the effect of softening of the skin structure and 8 regeneration significantly decreased, but if its content is greater than 18.75 g then. there was a problem in the production of the cream, the stability of the composition was reduced, the cream layered and its use was difficult. Vitamin E, α-tocopherol (Vitamin E, Alpha-tocopherol) - light yellow, translucent, viscous liquid with a weak aroma. Light oxidizes and becomes dark. Tocopherol is a hydrophobic substance, it contains the green parts of new plants, vegetable oils, it is a natural antioxidant that participates in inactivation of free radicals, protects cell membranes from collapse, including in the case of ultraviolet radiation, participates in protein synthesis, reduces seborrhea, activates seborrhoea, activates skin \ t regenerative preocesses [41]. The inclusion of Vitamin E in the cream formulation has led to a much faster rejuvenation of the epidermal lipid barrier in patients with metabolic syndrome. Optimal effect of α-tocopherol (vitamin E) content in cream composition 0.50-1.50 g. If its content was less than 0.50 g, the effect was greatly reduced, but if its content was higher than 1.50 g, the consistency of the cream changed, it became considerably more liquid, and difficult to use.
Metil-4-hidroksibenzoāts (Methyl paraben), CH3(C6H4(OH)COO) - baltas krāsas vai krēmkrāsas kristālisks pulveris, kas slikti šķīst ūdenī. Tas šķīst siltā ūdenī, metanolā, propilēnglikolā. To raksturo plašs antibakteriālās un pretsēnīšu iedarbības spektrs, tas dabiskā veidā sintezējas dažos augos, piemēram, mellenēs. To lieto pret pelējuma un gramnegatīvām baktērijām [42]. Cilvēka organismā viegli un pilnīgi uzsūcas caur ādu vai caur kuņģa-zamu traktu, sadalās vienkāršākās vielās un ātri tiek izvadīts ar urīnu, neuzkrājoties organismā. To izmanto par stabilizatoru un/vai prolongatoru, efektīvs ļoti zemās koncentrācijas, tīrā veidā un 0,25 %-5 % spirta šķīduma veidā. Optimālais metil-4-hidroksibenzoāta satura efekts krēma sastāvā 0,05-0,15 g. Ja tā saturs mazāks par 0,05 g, tad stabilizatora efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 0,15 g, tad izmainījās krēma konsistence, bija manāmi neizšķīdušie ieslēgumi, tika apgrūtināta krēma lietošana.Methyl 4-hydroxybenzoate (Methyl paraben), CH3 (C6H4 (OH) COO) - a white or cream-colored crystalline powder which is poorly soluble in water. It is soluble in warm water, methanol, propylene glycol. It is characterized by a broad spectrum of antibacterial and antifungal activity, which naturally synthesizes in some plants, such as blueberries. It is used against mold and gram-negative bacteria [42]. The human body is easily and completely absorbed through the skin or through the gastrointestinal tract, decomposes into simpler substances and is rapidly excreted in the urine without accumulation in the body. It is used as a stabilizer and / or prolonger, effective in the form of a very low concentration, pure and 0.25% -5% alcohol solution. The optimum effect of the methyl 4-hydroxybenzoate content in the cream composition is 0.05 to 0.15 g. If its content is less than 0.05 g, the stabilizer effect was significantly reduced, but if its content was higher than 0.15 g, the consistency of the cream changed, the insoluble inclusions were noticeable, the use of the cream was difficult.
Glicerīna monostearāts 60 (Glycery Stearaie) - baltas krāsas pulveris, kas iegūts no dabiskās stearīnskābes un glicerīna, ar perlamutra efektu (atstaro gaismu), ir vaskveidīgs, ciets emolents, emulgators un biezinātājs, to pievieno samaisīšanas fāzes stabilizācijas procesā. Tiek lietots kā stabilizējošs un strukturizējošs komponents, lai novērstu sastāva (kompozīcijas) hidrofobās un hidrofilās fāzes atdalīšanu, nosēdumu atdalīšanu [43]. Ja tā saturs mazāks par 2,52 g, tad biezinātāja efekts ievērojami 9 9LV 15082 samazinājās, bet, ja tā saturs lielāks par 4,20 g, tad izmainījās krēma konsistence, krēms kļuva ļoti biezs, tika apgrūtināta krēma lietošana.Glycerine Monostearate 60 (Glycery Stearaie) - a white powder obtained from natural stearic acid and glycerin, with a pearl effect (reflecting light), is a waxy, solid emolent, emulsifier and thickener, added to the mixing phase stabilization process. Used as a stabilizing and structuring component to prevent separation of the hydrophobic and hydrophilic phases of the composition (composition), removal of sediment [43]. If its content was less than 2.52 g, the thickening effect was significantly reduced to 9 9LV 15082, but if its content was higher than 4.20 g, the consistency of the cream changed, the cream became very thick, the use of the cream was difficult.
Cetilspirts (Cetyl alcohol, l-hexadecanoI), CH3(CH2)i4CH20H, vienatoma taukains spirts, cieta baltas krāsas viela, tauku bāzes sastāvā tiek lietots par emulgatoru un/vai saduļkotāju (opacifier), kas uzlabo konsistenci, paaugstina ūdens-eļļas maisījuma stabilitāti [44]. Lietošanai rekomendējamie grami: 3,78-6,29 g. Ja tā saturs mazāks par 3,78 g, tad emulgatora efekts ievērojami samazinājās, krēms noslāņojās, bet, ja tā saturs lielāks par 6,29 g, tad mainījās krēma konsistence, krēms kļuva pārāk šķidrs, tika apgrūtināta krēma lietošana.Cetyl alcohol (1-hexadecanoI), CH3 (CH2) i4CH2OH, mono-fatty alcohol, solid white color, used as a fat-based emulsifier and / or opacifier, which improves consistency, increases the stability of the water-oil mixture [44]. Recommended grams for use: 3.78-6.29 g. If its content is less than 3.78 g, the emulsifier effect decreased significantly, the cream layered, but if its content was greater than 6.29 g, the consistency of the cream changed, the cream became too liquid, the use of the cream was difficult.
Vidēji garo ķēžu triglicerīdi (Triglycerides medium-cham) - eļļains šķīdums, kas iegūts no kokoseļļas, nesšķīstošs ūdenī, sajaucams ar eļļām [45], Uzlabo krēma izvietojuma vienmērību uz ādas, izšķīdina lipofīlos savienojumus. Lietošanai rekomendējamie grami: 4,72-7,87 g. Ja tā saturs mazāks par 4,72 g, tad stabilizatora efekts ievērojami samazinājās, krēms noslāņojās, bet, ja tā saturs lielāks par 7,87 g, tad mainījās krēma konsistence, krēms kļuva pārāk šķidrs, tas apgrūtināja krēma lietošanu.Triglycerides medium-cham - an oily solution derived from coconut oil, insoluble in water, miscible with oils [45], Improves the smoothness of cream placement on the skin, dissolves lipophilic compounds. Recommended grams for use: 4.72-7.87 g. If its content is less than 4.72 g, the stabilizer effect decreased significantly, the cream layered, but if its content was higher than 7.87 g, the consistency of the cream changed, the cream became too liquid, which made it difficult to use the cream.
Baltais vazelīns (Vaselinum) - cietu un mīkstu augstmolekulāru ogļūdeņražu maisījums, kas iegūts, samaisot balto cerezīnu un parafīnu ar parfimērijas eļļu [46]. Vazelīnu lieto kā biezinātāju ādas krēmu un ziežu sastāvā. To lietojot ārēji, vazelīns sekmē ādas ūdens—lipīdu aizsargmantijas atjaunošanos, novērš šķidruma zudumu ādas šūnās, novērš ādas lobīšanos un plaisas. Vazelīns paredzēts sejas un roku ādas mīkstināšanai, tajā skaitā, ārējās vides negatīvo faktoru ietekmes izraisītajos gadījumos (saule, vējš, temperatūras izmaiņas). Ja tā saturs mazāks par 16,05 g, tad biezinātāja efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 26,74 g, tad mainījās krēma konsistence, krēms kļuva pārāk biezs, tas apgrūtināja krēma lietošanu.White Vaseline (Vaselinum) is a blend of hard and soft high molecular hydrocarbons obtained by mixing white ceresin and paraffin with perfume oil [46]. Vaseline is used as a thickener in skin cream and ointment. When used externally, Vaseline contributes to the rejuvenation of the skin's water-lipid protector, eliminates fluid loss in the skin cells, prevents skin peeling and cracks. Vaseline is designed to soften the skin of the face and hands, including in cases caused by the effects of external environmental factors (sun, wind, temperature changes). If its content is less than 16.05 g, the thickening effect was greatly reduced, but if its content was higher than 26.74 g, the consistency of the cream changed, the cream became too thick, which made it difficult to use the cream.
Makrogols-20-glicerma monostearāts (Macrogol), struktūrfonnula H0-(CH2-CH2-0)n-H, balts pulveris, veido ūdeņraža saites ar ūdens molekulām, to lieto medicīnā un kosmētikā kā savienojošo komponentu, izgatavojot bāzi ziedēm, to lieto arī kā stabilizējošo un strukturizējošo komponentu, kas padara sastāvu vienmērīgu [47]. Makrogola augstā hidrofilā pakāpe ļauj visefektīvāk veikt kompozīcijas homogenizāciju daudzumā 4,40-7,34 g, emulģējot jaunā krēma hidrofobos komponentus. Ja tā saturs mazāks par 4,40 g, tad biezinātāja efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 7,34 g, tad mainījās krēma konsistence, krēms kļuva pārāk biezs, tas apgrūtināja krēma lietošanu. 10 1,2-propāndioIs (l,2-propylenglycol), CH3CH(0H)CH20H, organiska viela, bezkrāsains, viskozs hidroskopisks šķidrums, bez aromāta, mitrumu uzturēšanas, mīkstināšanas un disperģēšanas aģents, labs šķīdinātājs [48]. Ar to pilnīgi sajaucas vairums mazmolekulāru organisku savienojumu, saturošu skābekli un slāpekli. Ja tā saturs mazāks par 6,29 g, tad biezinātāja efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 10,49 g, tad mainījās krēma konsistence, tas kļuva pārāk biezs un tika apgrūtināta krēma lietošana. Ūdens (Aqua) bāzes sastāvā ietilpst kā emulsijas „ūdens eļļā” daļa (kur ūdens - emulsijas hidrofilā daļa, eļļa un skvalēns - hidrofobā daļa). Lietošanai rekomendējamais daudzums: līdz 100 g. Ja tā saturs mazāks par 33,0 g, tad biezinātāja efekts ievērojami samazinājās, bet, ja tā saturs lielāks par 34,6 g, tad mainījās krēma konsistence, tas kļuva pārāk biezs, tika apgrūtināta krēma lietošana.Macrogol-20-glycerol monostearate (Macrogol), structural pellet H0- (CH2-CH2-0) nH, white powder, forms hydrogen bonds with water molecules, is used in medicine and cosmetics as a connecting component for making base for ointments, it is also used as a stabilizing agent and a structuring component that makes the composition smooth [47]. The high hydrophilic degree of macrogol allows the homogenization of the composition to be most efficient in an amount of 4.40-7.34 g, emulsifying the hydrophobic components of the new cream. If its content is less than 4.40 g, the thickening effect was greatly reduced, but if its content was higher than 7.34 g, the consistency of the cream changed, the cream became too thick, which made it difficult to use the cream. 10 1,2-Propanediol (1,2-propylenglycol), CH3CH (0H) CH2OH, organic matter, colorless, viscous hydroscopic liquid, odorless, moisture retaining, softening and dispersing agent, good solvent [48]. It completely blends most of the small molecular organic compounds containing oxygen and nitrogen. If its content is less than 6.29 g, the thickening effect was significantly reduced, but if its content was greater than 10.49 g, the consistency of the cream changed, becoming too thick and difficult to use. The water (Aqua) base contains as part of the water-in-oil emulsion (the hydrophilic part of the emulsion, the oil and the squalene - the hydrophobic part). Recommended use: up to 100 g. If its content is less than 33.0 g, the thickening effect was significantly reduced, but if its content exceeded 34.6 g, the consistency of the cream changed, it became too thick, the use of the cream was difficult.
Jaunais krēma sastāvs tika sekmīgi lietots, iegūstot dozētu formu tūbās pa 65,0 g (pa 30,0 g). Visi jaunā krēma sastāva komponenti, kā atsevišķi preparāti, atļauti lietošanai dermatoloģijā izgudrojumā minēto attiecību robežās. Jaunā krēma sastāvs un izgatavošanas tehnoloģija atbilst produktu drošības novērtējuma standarta kritērijiem saskaņā ar Eiropas Komisijas prasībām (Parlamenta un Padomes regula (EK) Nr.1223/2009 (2009. gada 30. novembris) par kosmētikas līdzekļiem, 11. pants). I.- Π. Krēma sastava piemēriThe new cream composition was successfully used to obtain a dosage form of 65.0 g (30.0 g) in tubes. All components of the new cream composition, as separate preparations, are permitted for use in dermatology within the scope of the invention. The composition and manufacturing technology of the new cream complies with the standard criteria for product safety assessment in accordance with European Commission requirements (Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products, Article 11). I.- Π. Examples of cream composition
Sastāvs satur: selēn-L-metionīns 0,0005-0,0015; α-tokoferola acetāts 0,50-1,50; skvalāns 11,25-18,75; metil-4- hidroksibenzoāts 0,05-0,15; glicerīna monostearāts 60 2,52-4,20; cetilspirts 3,78-6,29; vidēji garo ķēžu triglicendi 4,72-7,87; baltais vazelīns 16,05-26,74; makrogols-20-gliceriha monostearāts 4,40-7,34; 1,2-propāndiols 6,29-10,49; attīrīts ūdens līdz 100,0. 11 11LV 15082The composition contains: selenium-L-methionine 0.0005-0.0015; α-tocopherol acetate 0.50-1.50; squalane 11,25-18,75; methyl 4-hydroxybenzoate 0.05-0.15; glycerol monostearate 60 2.52-4.20; cetyl alcohol 3.78-6.29; medium length triglyceride 4.72-7.87; White Vaseline 16.05-26.74; macrogol-20-glycerol monostearate 4.40-7.34; 1,2-propanediol 6.29-10.49; purified water to 100.0. 11 11LV 15082
Krēma iegūšanas paņēmiensCream extraction technique
Jaunā krēma sastāva izgatavošanas sarežģītība saistīta ar to, ka skvalāns, glicerīns, triglicerīdi, vazelīns un α-tokoferols ir hidrofobas vielas, bet selēnmetionīns, makrogols, propāndiols - hidrofilas vielas.The complexity of making the new cream composition is due to the fact that squalane, glycerin, triglycerides, vaseline and α-tocopherol are hydrophobic substances, and selenomethionine, macrogol, propanediol - hydrophilic substances.
Pirmā krēma sastāva iegūšanas paņēmiens 1. Krēma hidrofobās daļas pagatavošana.Method of obtaining the first cream composition 1. Preparation of the hydrophobic part of the cream.
Krēma pagatavošanas traukā ūdens vannā 65-70 °C temperatūrā izkausē 2,52-4,20 g glicerīna monostearāta 60 un 3,78-6,29 g cetilspirta, pievieno un izkausē 16,05-26,74 g vazelīna, pievieno 11,25-18,75 g skvalāna un 4,72-7,87 g vidēji garo ķēžu triglicerīdus, maisa līdz viendabīgumam. Sakausējuma temperatūrai jābūt 60 °C. 2. Krēma hidrofilās daļas pagatavošana.Cream 2.52-4.20 g of glycerol monostearate 60 and 3.78-6.29 g of cetyl alcohol in a water bath at 65-70 ° C in a water bath, add and melt 16.05-26.74 g of Vaseline, add 11, 25-18.75 g of squalane and 4.72-7.87 g of medium chain triglycerides are stirred to homogeneity. The alloy temperature must be 60 ° C. 2. Preparation of the hydrophilic part of the cream.
Stikla vārglāzē 6,29-10,49 g 1,2-propāndiola 45-50 °C temperatūrā izšķīdina 0,05-0,15 g metil-4-hidroksibenzoāta, pievieno daļu no atlikušā attīrīta ūdens, samaisa, pievieno 4,40-7,34 g makrogola-20-gliceiīna monostearāta, izšķīdina, sildot līdz 60 °C temperatūrai. 3. Krēma pagatavošanas traukā pie hidrofobās daļas pievieno hidrofilo daļu, maisa krēma maisīšanas iekārtā 15-20 minūtes, kamēr masa atdziest līdz 30-35 °C temperatūrai. 4. Krēma masai pievieno 0,50-1,50 g α-tokoferola acetāta un 0,0005-0,0015 g selēn-L-metionīna, kas izšķīdināts daļā no atlikušā attīrītā ūdens. Maisa krēma maisīšanas iekārtā 10 minūtes līdz viendabīgas masas iegūšanai.In a glass beaker, 6.29 to 10.49 g of 1,2-propanediol are dissolved at 0.05 to 0.15 g of methyl 4-hydroxybenzoate at 45-50 ° C, part of the residual purified water is added, stirred, 4.40- 7.34 g of macrogol-20-glycerine monostearate, dissolved by heating to 60 ° C. 3. Add a hydrophilic portion to the hydrophobic portion of the cream preparation vessel, stir the cream in the mixing machine for 15-20 minutes until the mass cools to 30-35 ° C. 4. Add 0.50 to 1.50 g of α-tocopherol acetate and 0.0005-0.0015 g of selenium-L-methionine dissolved in a portion of the remaining purified water to the cream mass. Stir the cream in the mixing machine for 10 minutes to obtain a homogeneous mass.
Otrā sastāva iegūšanas paņēmiens - analoģisks pirmajam. Iegūto krēmu fasē alumīnija tūbās pa 65,0 g (pa 30,0 g).The method of obtaining the second composition is analogous to the first one. The resulting cream is packed in aluminum tubes of 65.0 g (30.0 g).
Krēma sastāvs ir homogēna masa baltā krāsā vai baltā krāsā ar dzeltenīgu nokrāsu, vāji izteiktu un patīkamu aromātu, atbilstošu lietotajai tauku bāzei.The cream is homogenous in white or white with a yellowish tinge, a weak and pleasant aroma, suitable for the fat base used.
Krēms paredzēts sejas ādas, kakla un dekoltē zonas epidermālās lipīdu barjeras atjaunošanai pacientiem ar metabolisko sindromu. Krēmam piemīt komponentu biosaderiba, tas viegli iesūcas ādā, to pārklājot ar plānu, elastīgu slāni, krēma pH 4,0-5,0. Krēmam piemīt ādu nomierinoša iedarbība, tas mazina niezi un iekaisumu, to ilgstoši lietojot, tas neizraisa kairinājumus un blaknes.The cream is designed to rejuvenate the epidermal lipid barrier of the face, neck and décolleté patients with metabolic syndrome. The cream has a component biocompatibility, it is easily absorbed into the skin, covered with a thin, supple layer, the cream pH 4.0-5.0. The cream has a soothing effect on the skin, it relieves itching and inflammation by prolonged use, it does not cause irritation and side effects.
Lai novērtētu krēma īpašības, saistībā ar ādas epidermālās lipīdu barjeras profilaksi un/vai atjaunošanu, izmantojot „LIPEX” (Rīga) dermatoloģijas klīnikas un 12 estētiskās medicīnas bāzi, tika veikts prospektīvs klīnisks pētījums, kura ietvaros informatīvas, brīvprātīgas piekrišanas apstākļos tika aicināti vīrieši un sievietes ar metabolisko sindromu vecumā 39-55 gadi. Rezultātā tika atlasītas 2 vienveidīgas pacientu grupas ar metabolisko sindromu, kuri nesmēķē, neapmeklē solāriju, ar vidēju insolācijas pakāpi (vidēja saules ekspozīcija, visu sezonu pavada Vidus- un Ziemeļeiropas apstākļos). Pirmās grupas (1. grupa, n=12) un otrās grupas (2. grupa, n=15) sastāvā iekļauti pacienti, kuriem diagnosticēts metaboliskais sindroms. Metaboliskā sindroma diagnoze tika noteikta, pamatojoties uz izmaiņu kompleksu, saskaņā ar Starptautisko slimību klasifikatoru (10. izdevums) [1] un ASV Nacionālā veselības aizsardzības institūta speciālistu veikto analīzi: metaboliskais sindroms tika noteikts pēc trijiem vai vairākiem simptomiem: • aptaukošanās abdominālais tips - vidukļa apkārtmēra rādītājs lielāks par 89 cm sievietēm un lielāks par 102 cm vīriešiem, • glikozes līmenis tukšā dūšā - lielāks par 6,1 mmol/1, • triglicerīdu līmenis - lielāks par 1,69 mmol/1, • zema blīvuma lipoproteīnu līmeņa pazemināšanās: sievietēm - mazāks par 1,29 mmol/1; vīriešiem - mazāks par 1,04 mmol/1, • arteriālā asinsspiediena līmenis 135/85 mmHg. Pētījuma protokols, vienošanās un dalības protokols, dalības anketa atbilst Pasaules Medicīnas asociācijas (PMA) Helsinku deklarācijas ētiskajiem un humānisma principiem medicīnā, kā an apstiprināti Rīgas Stradiņa universitātes Ētikas komisijā. Interešu konflikts nepastāv. 1. grupas pacientiem (n=12), pēc iepriekšējas klīniskās izmeklēšanas, krēms tika nozīmēts ilgstoši (2 mēnešus, aktīvas UV insolācijas laikā, maija un jūnija mēnešos). Krēmu uzklāja plānā kārtiņā, 2 reizes dienā (rītā un vakarā) uz tīras sejas ādas, kakla un dekoltē zonas. 2. grupas pacienti krēmu nelietoja. Abās grupās klīniskos pētījumus atkārtoja pēc 14, 30 un 60 dienām, sākot no krēma lietošanas sākuma.In order to evaluate the properties of the cream, in connection with the prevention and / or restoration of the epidermal lipid barrier of the skin using the LIPEX (Riga) dermatology clinic and 12 aesthetic medicine base, a prospective clinical study was conducted in which men and women were invited under informative, voluntary consent. with metabolic syndrome aged 39-55 years. As a result, 2 homogeneous groups of patients with non-smoking metabolic syndrome were selected, did not go to the solarium, with a moderate degree of insolation (medium exposure, spent all season in Central and North Europe). The first group (Group 1, n = 12) and the second group (Group 2, n = 15) include patients diagnosed with metabolic syndrome. The diagnosis of metabolic syndrome was based on a complex of changes, according to an analysis by the International Classification of Diseases (10th edition) [1] and the US National Institute of Health: metabolic syndrome was identified by three or more symptoms: • abdominal type of obesity - waist circumference greater than 89 cm for women and over 102 cm for men, • fasting glucose - greater than 6.1 mmol / l, - triglycerides higher than 1.69 mmol / 1, - low density lipoproteins: women less than 1.29 mmol / l; for men - less than 1.04 mmol / l, • arterial blood pressure level of 135/85 mmHg. The protocol of the study, the agreement and the protocol of participation, the participation questionnaire correspond to the ethical and humanist principles of medicine in the World Medical Association (PMA) Helsinki Declaration, as approved by the Riga Stradins University Ethics Commission. There is no conflict of interest. In group 1 patients (n = 12), after a previous clinical trial, the cream was prescribed for a long time (2 months, during active UV insolation, in May and June). The cream was applied in a thin layer twice a day (morning and evening) on a clean face skin, neck and décolleté area. Group 2 patients did not use the cream. In both groups, clinical trials were repeated after 14, 30 and 60 days from the start of the cream application.
Klīniskie pētījumi ietvēra antropometriskos datus (ķermeņa masas indekss, vidukļa apkārtmērs, arteriālais asinsspiediens), asins analīzi (glikoze, lipoproteīni). Lai novērtētu ādas epidermālo lipīdu barjeru, veica siaskopiju un dermatoskopiju (siaskops MoleVievv SIAscope V Handset, Astron, Lielbritānija un dermatoskops HEINE alpha + Heine Optotechnic, Vācija). Ādas reljefa un morfoloģijas stāvoli (turgors, mikroreljefs un papilomu esamība) novērtēja ar dermatoskopijas 13 13LV 15082 starpniecību. Pigmentāciju un lobīšanos novērtēja, izmantojot siaskopiju. plī-metrijas mērījumus veica ar pH-metrijas sensora palīdzību. Transepidermālā ūdens zuduma mērījumus veica ar sensora Tewameter® TM 300, Courage + Khazaka eleclronic GmbH, Vācija, (tevametrija) palīdzību. Ar šiem sensoriem iegūtu pētījuma rezultātu aprēķinu un saglabāšanu veica, izmantojot programmnodrošinājumu datu bāzē SPSS 20,0 {Microsoft, ASV). Rezultātus reģistrēja skaitliskās vērtībās. Korneometrijas rādītāju normālo vērtību robežas bija no 40 un augstākas, tevametrijas - zemākas par 12, pH-metrija.s - robežās no 3,5 līdz 5,8. Katru pazīmi novērtēja pēc skalas no 0 līdz 3 ballēm: 0 - pazīme neeksistē, 2 - pazīme izteikta mēreni, 3 - pazīme izteikta spēcīgi. Vērtēja strukturālo izmaiņu datus un veica ādas imunitātes vērtējumu: veica histoloģiskos pētījumus, izmantojot gaismas mikroskopiju. Gaismas mikroskopijas palielinājums - 400 reizes, ar imūnhistoķīmijas metožu palīdzību, lietojot CDla, CD31, CD34, CD3, CD8. 2. tabula - ar metabolisko sindromu sirgstošu abu pacientu grupu klīnisko pētījumu rezultāti. 2. tabula 1. grupa, jaunais krēms, n=12 2. grupa, krēmu neizmanto, n=15 Ādas turgors (pēc skalas 0-1-2-3) vidējs, augsts vidējs, zems Mitrinājums Transepidermālais ūdems zudums un komeometrija 27,2±1,1 19,1 ±1,2 Lobīšanās (pēc skalas 0-1-2-3) Vidējais indekss 1,8 Lielo suņu daudzums 34,4% Vidējais indekss 2,6 Lielo šūnu daudzums 65,7+5% Lentigo, pigmentācijas nevienmērīgums (pēc skalas 0-1-2-3) Vidējais indekss 1,2 Vidējais indekss 2,8 pH Robežās 5,5-5,8 Robežās 5,4-5,6 Ādas reljefs (pec skalas 0-1-2-3) Vidējais indekss 1,6 Vidējais indekss 2,8 14Clinical studies included anthropometric data (body mass index, waist circumference, arterial blood pressure), blood test (glucose, lipoproteins). To evaluate the epidermal lipid barrier of the skin, siaskopy and dermatoscopy were performed (mole MoleVievv SIAscope V Handset, Astron, UK and the dermatoscope HEINE alpha + Heine Optotechnic, Germany). The states of skin relief and morphology (turgor, microrelief and the presence of papillomas) were evaluated by dermatoscopy 13 13LV 15082. Pigmentation and peeling were evaluated using siachopy. p-metric measurements were performed with a pH-meter. Measurements of transepidermal water loss were performed with the help of the Tewameter® TM 300, Courage + Khazaka eleclronic GmbH, Germany (camelmeter). The calculation and retention of the study results obtained with these sensors was performed using the software in the database SPSS 20.0 {Microsoft, USA). The results were recorded in numerical values. The range of normal values for corneometry values ranged from 40 and higher, camelmeters below 12, pH-metrics from 3.5 to 5.8. Each attribute was rated on a scale from 0 to 3: 0 - no sign, 2 - sign moderate, 3 - sign strong. Evaluation of structural change data and assessment of skin immunity: histological studies were performed using light microscopy. Magnification of light microscopy - 400 times, by immunohistochemical methods using CDla, CD31, CD34, CD3, CD8. Table 2 - Results of clinical trials of both groups of patients with metabolic syndrome. Table 2 Group 1, New Cream, n = 12 Group 2, No Cream, n = 15 Skin Markers (0-1-2-3 scale) Medium, Medium, Low Moisture Transepidermal Water Loss and Cometry 27, 2 ± 1.1 19.1 ± 1.2 Hatching (by scale 0-1-2-3) Average Index 1.8 Large Dogs 34.4% Average Index 2.6 Large Cells 65.7 + 5% Lentigo, unevenness of pigmentation (by scale 0-1-2-3) Average index 1.2 Average index 2.8 pH Within limits 5.5-5.8 Within limits 5.4-5.6 Skin relief (on scale 0-1 -2-3) Average Index 1.6 Average Index 2.8 14
Veicot pētījumu, vairumam pacientu no abām grupām, noteica sūdzības par ādas sausumu un pastiprinātu lobīšanos.In the study, most patients in both groups were complaining of dry skin and increased peeling.
Klīnisko pētījumu rezultātā 1. grupas pacientiem (12), kuri lietoja jaumo krēmu 2 mēnešus, tika iegūti šādi rādītāji: 1) ādas mitrums bija 27, 2±1, t.i., augstāks, salīdzinot ar 2. grupas pacientiem (15) - 19,1±1,2; 2) lobīšanās - 1,8 bija 1. grupas pacientiem un 2,6 - 2. grupas pacientiem, t.i., lobīšanās bija vairāk izteikta 2. grupas pacientiem; 3) pigmentācija - 1,2 bija 1. grupas pacientiem un 2,8 - 2. grupas pacientiem, t.i., pigmentācija bija vairāk izteikta 2. grupas pacientiem; 4) ādas reljefs - 1,6 bija 1. grupas pacientiem un 2,8 bija 2. grupas pacientiem, t.i., papilomu esamība un ādas elastoze bija vairāk izteikta 2. grupas pacientiem. Tādējādi 1. grupas pacientiem, kuri lietoja jauno krēmu 2 mēnešu laikā, konstatēja ādas barjerfunkcijas stāvokļa, ādas reljefa un elastības atjaunošanos.As a result of clinical studies, patients of Group 1 patients (12) who took cream for 2 months received the following indicators: 1) skin moisture was 27, 2 ± 1, ie higher than in group 2 patients (15) - 19, 1 ± 1.2; 2) peeling 1.8 was in group 1 patients and 2.6 in group 2 patients i.e. peeling was more pronounced in group 2 patients; 3) pigmentation - 1.2 was in group 1 patients and 2.8 - in group 2 patients, i.e. pigmentation was more pronounced in group 2 patients; 4) skin relief - 1.6 was in group 1 patients and 2.8 was in group 2 patients, i.e. the presence of papillomas and skin elasticity was more pronounced in group 2 patients. Thus, patients in Group 1 who took the new cream within 2 months showed a restoration of skin barrier function, skin relief, and elasticity.
Saskaņā ar datiem, kas iegūti pētot ādas imunitāti, ādas imunitātes šūnu (Langerhansa šūnas) aktivitāte 2. grupas pacientiem bija pazemināta. Turklāt 2. grupas pacientu ādā bija novērojama limfocitārā infiltrācija un Birbeka granulu uzkrāšanās (liecina par iekaisuma procesu). 1. grupas pacientu ādā jaunā krēma lietošanas fonā pieauga imūnkompetento Langerhansa šūnu daudzums, par divām reizēm samazinājās Birbeka granulu skaits, kas liecināja par vietējās ādas imunitātes uzlabošanos.According to data from skin immunity studies, the activity of skin immune cells (Langerhans cell) was reduced in group 2 patients. In addition, lymphocytic infiltration and accumulation of Birbek pellets were observed in the skin of patients in Group 2 (indicative of an inflammatory process). In the skin of Group 1 patients, the number of immunocompetent Langerhans cells increased in the background of the use of the new cream, and the number of Birbeka pellets decreased two times, suggesting an improvement in local skin immunity.
Veiktie pētījumi pierādīja, ka jaunajam krēma sastāvam piemīt kosmētiskās un ārstnieciski-profilaktiskās īpašības, tas atjauno ādas epidermālo lipīdu barjeru un ādas baņcrfunkciju pacientiem ar metabolisko sindromu: uzlabo ādas turgoru un mitruma stāvokli, atjauno elastību un ādas gludo reljefu, samazina pigmentācijas izpausmes, iekaisuma papilomas.Studies have shown that the new cream composition has cosmetic and curative-prophylactic properties, restores skin epidermal lipid barrier and skin function in patients with metabolic syndrome: improves skin turgor and moisture, restores elasticity and smooth skin texture, reduces pigmentation, inflammation papillomas, inflammatory papillomas .
Izgudrojuma sarežģītība saistīta ar to, ka nebija zināmi jaunā sastāva komponenti un to savstarpējā attiecība, līdz ar kuriem jaunais sastāvs varētu veikt efektīvu atjaunojošu iedarbību uz ādas epidermālo lipīdu barjeru. Krēma izstrādāšanu papildus sarežģīja apstāklis, ka jaunā sastāva komponenti bija gan hidrofilas (selēnmetionīns), gan hidrofobas (E vitamīns, skvalāns) vielas. Nebija zināmi apstākļi, kuros jaunā sastāva hidrofilie un hidrofobie komponenti varētu būt savienojami vienā krēmā, kuram piemīt augsta taukainības pakāpe. Eksperimentāli iegūtie komponenti, to savstarpējā attiecība un jaunā krēma sastāva iegūšanas 15 15LV 15082 tehnoloģiskie apstākļi ļāva izgatavot stabilu homogēnu jaunā krēma sastāvu, kas saglabā savu efektivitāti un stabilu konsistenci istabas temperatūrā 6-8 mēnešu laikā.The complexity of the invention is due to the fact that the new composition components and their interrelationship were not known, so that the new composition would have an effective rejuvenating effect on the epidermal lipid barrier of the skin. The addition of the cream was further complicated by the fact that the components of the new composition were both hydrophilic (selenomethionine) and hydrophobic (vitamin E, squalane) substances. There were no circumstances in which the hydrophilic and hydrophobic components of the new composition could be combined in one cream with a high degree of grease. The experimental components, their relationship and the technological conditions of the new cream 15 15LV 15082 made it possible to produce a stable homogeneous composition of the new cream, which maintains its efficiency and stable consistency at room temperature for 6-8 months.
Jaunā krēma sastāvs ir ūdens un tauku, taukveidīgu un citu vielu maisījums. Augstais lauku sastāva un taukveidīgu vielu procentuālais sastāvs svarīgs, lai sasniegtu ādas epidermālās lipīdu barjeras un ūdens-lipīdu mantijas atjaunošanas efektu. Pastāv tehnoloģiskas grūtības, savienojot tādu skaitu taukvielu, bez gatavā produkta noslāņošanās riska. Šāda tipa krēmiem ir svarīgi lietot īpašus emulgatorus, kuru iekļaušana pieteiktajā attiecībā ļauj iegūt jaunā krēma sastāva vienmērigu krēmveida konsistenci, kas saglabā stabilitāti uzglabāšanas procesā un gatavās zāļu formas ērtu ekstrūziju no iepakojuma (tūbas), kas ļoti svarīgi pacienta lietošanas ērtībai. Pieteiktā jaunā krēma sastāva atšķirīgās īpatnības ir tajā apstāklī, ka par emulgatoriem tiek izmantotas vairākas vielas, katrai no tām piemīt struktūrveidojošas un emulģējošas īpašības. Vienlaikus lietotie emulgatori, kurus ievada krēma sastāvā stingri noteiktā secībā, saskaņā ar pieteiktā izgudrojuma tehnoloģiju nodrošina efektīvu un stabilu jaunā krēma kompleksā sastāva saglabāšanu. Hidrofilo komponentu (ūdens, selēnmetionīns, glicerīns) noteikta savstarpējā attiecība un šķīdinātāju (cetilspirts, glicerīns) noteikta savstarpējā attiecība ļauj saglabāt hidrofilo (selēnmetionīns) un hidrofobo (tokoferols, skvalāns, trigliceridi) vielu aktivitāti, kuras iekļautas krēma kompozīcijas sastāvā.The composition of the new cream is a mixture of water and fat, fat and other substances. The high percentage of field composition and fatty substances is important in achieving the skin's epidermal lipid barrier and water-lipid restoration effect. There are technological difficulties in connecting such a quantity of fat without the risk of stratification of the finished product. For these types of creams, it is important to use special emulsifiers, the inclusion of which in the proposed application allows to obtain a smooth creamy consistency of the new cream composition, which preserves the stability of the storage process and easy extrusion of the finished dosage form from the package (tubes), which is very important for the convenience of the patient. The different peculiarities of the composition of the new cream applied are the fact that several substances are used as emulsifiers, each of them has structuring and emulsifying properties. At the same time, emulsifiers used in the composition of the cream in a strictly defined order, in accordance with the technology of the claimed invention, provide an effective and stable preservation of the complex composition of the new cream. A certain ratio of hydrophilic components (water, selenomethionine, glycerol) and the ratio of solvents (cetyl alcohol, glycerol) to the activity of hydrophilic (selenomethionine) and hydrophobic (tocopherol, squalane, triglycerides) included in the composition of the cream composition.
Jaunā krēma sastāvs netika konstatēts zinātniski tehniskās un patentu informācijas avotos. Veiktie eksperimentālie un klīniskie pētījumi liecina, par atbilstību kritērijam «izgudrojuma līmenis”The composition of the new cream was not found in scientific-technical and patent information sources. Experimental and Clinical Trials Completed to the 'Invention Level' Criterion
RŪPNIECISKĀ IZMANTOŠANAINDUSTRIAL USE
Izstrādātas 2 rūpnieciskās krēma formas - 65,0 g (pa 30,0 g) gaismas necaurlaidīgās alumīnija tūbās. Abu jaunā krēma sastāva formu stabilitāte un tehnoloģiskās īpašības saglabājas 6 mēnešu laikā istabas temperatūrā.Developed in 2 industrial cream shapes - 65.0 g (30.0 g) in opaque aluminum tubes. Stability and technological properties of both forms of the new cream remain for 6 months at room temperature.
Informācijas avoti 1. http://www.polismrd.com/articles-metabolicheskijj-prichiny-simptomy-i-priznaki.html., 08.07.2015. 2. Pat. Ru 2182822, Cl, 2002, A61K9/06; A61P17/02. 3. http://cosmocat.ru/publ/4-l-0-428, 08.07.2015. 4. http://www.frauleto.ru/articles/ceramidv-i-kozha/, 08.07.2015. 16 5. http:/Amari.ru/tematicheskie-stati/zdorove/immunitetJkozhi.html, 08.07.2015. 6. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med. 2008;75:772,774, 776-777. doi: 10.3949/ccjm.75.11.772. passīm. 7. Elias, PM, Holleran, WM, Calhouti, CJ, Quiec, D, Brovvn, BE, Bekne, M, Feingold, KR: Permeability barrier homeostasis. The role of lipid processing. In: Loden M, Maibach HI (eds). Dry Skin and Moisturizers: Chemistry and Function. 2000 Dermatology: Clinical and Basic Science Series. New York: CRC Press, p 59-70. 8. Fluhr JW, Feingold KR, Elias PM. Transcpidermal watcr loss rcflects penneability barrier status: validation in human and rodent in vivo and ex vivo models. Exp Dermatol 2006; 15:483-492. 9. Fluhr JW, Elias PM. Stratum comeum pH: Formation and function of the ’acid mantle'. Exog. Dermatol. 1,163-175(2002). 10. Serup J, et al., eds. Handbook of non-invasive methods and the skin. 2nd ed. CRC press, 2006. 11. Wilhelm K-P, et al., eds. Bioengineering of the skin: skin imaging and analysis. 2nd ed., 2007. 12. Pat. JP 2013516441, A, 2013, A61K8/97, A61Q19/00. 13. Pat. US 2013129803, A, 2013, A61K8/97, A61Q19/00. 14. Pat. RU 2458676, C2,2012, A61K8/97, A61Q19/00. 15. Bissett DL, Chatterjee R, Hannon DP. Photoprotective effect of superoxide-scavenging antioxidants against ultraviolet radiation-induced chronic skin damage in the hairless mouse. Photodermatol Photoimmimol Photomed. 1990;7:56-62. 16. Burke KE, Clive J, Combs GF, Jr, Commisso J, Keen CL, Nakamura RM. Effects of topical and oral vitamin E on pigmentation and skin cancer induced by ultraviolet irradiation in Skh:2 hairless mice. Nutr Cancer. 2000;38:87-97. doi: 10.1207/S15327914NC38113. 17. Chen L, Hu JY, Wang SQ. The role of antioxidants in photoprotection: a critical review. J Am Acad Dermatol. 2012;67:1013-1024. doi: 10.1016/j.jaad.2012.02.009. 18. Bikle D, Teichert A, Hawker N, Xie Z, Oda Y. Sequential regulation of keratinocyte differentiation by l,25(OH)2D3, VDR, and its coregulators. J Steroid Biochem Mol Biol. 2007;103:396-404. doi: 17 17LV 15082 10.1016/j .jsbmb.2006.12.063. 19. Takema Y, Hattori M, Aizawa K. The relationship between quantitative changes in collagen and formation of vvrinkles on hairless mouse skin after chronic UV irradiation. J Dermatol Sci. 1996;12:56-63. doi: 10.1016/0923-1811(95)00467-X. 20. Sardy M. Role of matrix metalloproteinases in skin ageing. Connect Tissue Res. 2009;50:132-138. doi: 10.1080/03008200802585622. 21. Steenvoorden DP, Beijersbergen van Henegouwen G. Protection againsL UV-induced systemic immunosuppression in mice by a single topical application of the antioxidant vitamīns C and E. Int J Radiat Biol. 1999;75:747-755. doi: 10.1080/095530099140096. 22. Van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther. 2006;19:252-263. 23. Burke The effects of topical L-selenomethionine on protection against UVB-induced skin cancer when given before, during, and after UVB exposure//J Drugs Dermatol 2014 Oct;13(10):1214-23. 24. Kircik LH, Del Rosso JQ, Aversa D. Evaluating Clinical Use of a Ceramide-dominant, Physiologic Lipid-based Topical Emulsion for Atopic Dermatitis. J Clin Aesthet Dermatol. 2011;4:34-40. 25. Callen J, Chamlin S, Eichenfield LF, et al A systematic review of the safety of topical therapies for atopic dermatitis. Br J Dermatol. 2007 Feb;156(2):203-21. Revievv. PubMed PMID: 17223859. 26. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders// Am J Clin Dermatol. 2003;4(11):771-88. 27. Jurkievvicz BA, Bissett DL, Buettner GR. Effect of topically applied tocopherol on ultraviolet radiation-mediated ffee radical damage in skin. J Invest Dermatol. 1995;104:484-488, 28. http://www.vaseline.us, 08.07.2015. 29. http://www.faqs.org/patents/app/20080319069,08.07.2015. 30. http://www.roz.ru/selena/, 08.07.2015. 31. Verdier-Sevrain S, Bonte F. Skin hydration: a review on its molecular mechanisms. J Cosmet Dermatol 2007; 6: 75-82. 32. Pat. KR 101504908, Bl, 2015, A61K8/97. 33. Pat. KR 20140148149, A, 2014, A61K8/97; A61P17/00. 18 34. Pat. KR 20150008825, A, 2015, A61K8/14; A61Q19/00. 35. Pat. KR 20150011324, A, 2015, A61K8/97; A61Q19/00. 36. Pat. WO 2015013634, A, 2015, A61K8/68; A61Q19/00. 37. http://www.drugs.coin/mtm/selenium-sulfide-topical.html, 08.07.2015. 38. Wu L, Huang ZH, Burau RG. Selenium accumulation and selenium-salt cotolerance in five grass species. Crop Sci. 1988;28:517-522. 39. Squalane: the natūrai moisturizer", by Rosenthal, Maurice L. in Chemistry and Manufacture of Cosmetics (3rd Edition), Editor: Schlossman, Mitchell L. (2002), 3(Bk. 2), 869-875. 40. Final report on the safety assessment of squalane and squalene". Journal of the American College of Toxicology 1 (2): 37-56. 1982. 41. http://www.drugs.com/mmx/alpha-tocopherol.html, 08.07.2015. 42. Soni MG, Taylor SL, Greenberg NA, Burdock GA (October 2002). "Evaluation of the health aspects of methyl paraben: a review of the published literature". Food Chem. Toxicol. 40 (10): 1335-73. 43. Jens Rirk T.auridsen (1976). "Food emulsifiers: Surface activity, edibility, manufacture, composition, and application". Journal of the American Oil Chemists' Society 53 (6): 400-407. 44. Ballmann C, Mueller BW. Stabilizing effect of cetosteaiyl alcohol and glyceryl monostearate as co-emulsifiers on hydrocarbon-fi:ee 0/W glyceride creams. Pharm Dev Technol. 2008;13(5):433-45. 45. Akoh, Casimir C. (2006). Handbook of Functional Lipids. Washington, DC: Taylor & Francis. 46. http://www.drugs.com/sfx/vaseline-dermatology-fonnula-side-efFects.html, 08.07.2015. 47. W. Sterry, R. Paus, W, Burgdorf; Dermatology, Stuttgart [etc.] : Thieme, 2006, p. 586. 48. Ullmann's Encyclopedia of Industrial Chemistry. Copyright © 1999-2014 by John Wiley and Sons, Inc.Sources of Information 1. http://www.polismrd.com/articles-metabolicheskijj-prichiny-simptomy-i-priznaki.html., 08.07.2015. 2. Pat. Ru 2182822, Cl, 2002, A61K9 / 06; A61P17 / 02. 3. http://cosmocat.ru/publ/4-l-0-428, 08.07.2015. 4. http://www.frauleto.ru/articles/ceramidv-i-kozha/, 08.07.2015. 16 5. http: /Amari.ru/tematicheskie-stati/zdorove/immunitetJkozhi.html, 08.07.2015. 6. Van Hattem S, Bootsma AH, Thio HB. Skin manifestations of diabetes. Cleve Clin J Med. 2008; 75: 772,774, 776-777. doi: 10.3949 / ccjm.75.11.772. passports. 7. Elias, PM, Holleran, WM, Calhouti, CJ, Quiec, D, Brovvn, BE, Bekne, M, Feingold, KR: Permeability barrier homeostasis. The role of lipid processing. In: Loden M, Maibach HI (eds). Dry Skin and Moisturizers: Chemistry and Function. 2000 Dermatology: Clinical and Basic Science Series. New York: CRC Press, pp. 59-70. 8. Fluhr JW, Feingold KR, Elias PM. Transcpidermal watcr loss rcflects penneability barrier status in vivo and ex vivo models. Exp Dermatol 2006; 15: 483-492. 9. Fluhr JW, Elias PM. Stratum comeum pH: Formation and function of the acid mantle. Exog. Dermatol. 1.163-175 (2002). 10. Serup J, et al., Eds. Handbook of non-invasive methods and the skin. 2nd ed. CRC press, 2006. 11. Wilhelm K-P, et al., Eds. Bioengineering of the skin: skin imaging and analysis. 2nd ed., 2007. 12. Pat. JP 2013516441, A, 2013, A61K8 / 97, A61Q19 / 00. 13. Pat. US 2013129803, A, 2013, A61K8 / 97, A61Q19 / 00. 14. Pat. RU 2458676, C2,2012, A61K8 / 97, A61Q19 / 00. 15. Bissett DL, Chatterjee R, Hannon DP. Photoprotective effect of superoxide scavenging antioxidants against ultraviolet radiation-induced chronic skin damage in the hairless mouse. Photodermatol Photoimmimol Photomed. 1990; 7: 56-62. 16. Burke KE, Clive J, Combs GF, Jr., Commisso J, Keen CL, Nakamura RM. Effects of topical and oral vitamin E is a pigmentation and skin cancer induced by ultraviolet irradiation in Skh: 2 hairless mice. Nutr Cancer. 2000; 38: 87-97. doi: 10.1207 / S15327914NC38113. 17. Chen L, Hu JY, Wang SQ. The role of antioxidants in photoprotection: a critical review. J Am Acad Dermatol. 2012; 67: 1013-1024. doi: 10.1016 / Jan. 2012.02.009 18. Bikle D, Teichert A, Hawker N, Xie Z, Oda Y. Sequential regulation of keratinocyte differentiation by 1, 25 (OH) 2D3, VDR, and its coregulators. J Steroid Biochem Mol Biol. 2007; 103: 396-404. doi: 17 17LV 15082 10.1016 / j .jsbmb.2006.12.063. 19. Takema Y, Hattori M, Aizawa K. J Dermatol Sci. 1996; 12: 56-63. doi: 10.1016 / 0923-1811 (95) 00467-X. 20. Sardy M. Role of matrix metalloproteinases in skin aging. Connect Tissue Res. 2009; 50: 132-138. doi: 10.1080 / 03008200802585622. 21. Steenvoorden DP, Beijersbergen van Henegouwen G. Protection AgainsL UV-induced systemic immunosuppression in mice by a single topical application of the antioxidant vitamin C and E. Int J Radiat Biol. 1999; 75: 747-755. doi: 10.1080 / 095530099140096. 22. Van de Kerkhof PC. Update is a retinoid therapy of psoriasis in the dermatology. Dermatol Ther. 2006; 19: 252-263. 23. Burke The effects of topical L-selenomethionine on protection against UVB-induced skin cancer when given before, and after UVB exposure // J Drugs Dermatol 2014 Oct; 13 (10): 1214-23. 24. Kircik LH, Del Rosso JQ, Aversa D. Evaluating Clinical Use of a Ceramide-dominant, Physiologic Lipid-based Topical Emulsion for Atopic Dermatitis. J Clin Aesthet Dermatol. 2011; 4: 34-40. 25. Callen J, Chamlin S, Eichenfield LF, et al. A systematic review of the topical therapies for atopic dermatitis. Br J Dermatol. 2007 Feb 156 (2): 203-21. Revievv. PubMed PMID: 17223859. 26. Loden M. Role of topical emollients and moisturizers in the treatment of dry skin barrier disorders // Am J Clin Dermatol. 2003; 4 (11): 771-88. 27. Jurkievvicz BA, Bissett DL, Buettner GR. Effect of topically applied tocopherol is ultraviolet radiation-mediated ffee radical damage in skin. J Invest Dermatol. 1995; 104: 484-488, 28. http://www.vaseline.us, 08.07.2015. 29. http://www.faqs.org/patents/app/20080319069,08.07.2015. 30. http://www.roz.ru/selena/, 08.07.2015. 31. Verdier-Sevrain S, Bonte F. Skin hydration: a review on its molecular mechanisms. J Cosmet Dermatol 2007; 6: 75-82. 32. Pat. KR 101504908, B1, 2015, A61K8 / 97. 33. Pat. KR 20140148149, A, 2014, A61K8 / 97; A61P17 / 00. 18 34. Pat. KR 20150008825, A, 2015, A61K8 / 14; A61Q19 / 00. 35. Pat. KR 20150011324, A, 2015, A61K8 / 97; A61Q19 / 00. 36. Pat. WO 2015013634, A, 2015, A61K8 / 68; A61Q19 / 00. 37. http: //www.drugs.coin/mtm/selenium-sulfide-topical.html, 08.07.2015. 38. Wu L, Huang ZH, Burau RG. Selenium accumulation and selenium salt in five grass species. Crop Sci. 1988; 28: 517-522. 39. Squalane: the kind of moisturizer, "by Rosenthal, Maurice L., in Chemistry and Manufacture of Cosmetics (3rd Edition), Editor: Schlossman, Mitchell L. (2002), 3 (Bk. 2), 869-875. 40. Final report on squalane and squalene ". Journal of the American College of Toxicology 1 (2): 37-56. 1982. 41. http://www.drugs.com/mmx/alpha-tocopherol.html, 08.07.2015. 42. Soni MG, Taylor SL, Greenberg NA, Burdock GA (October 2002). " Evaluation of the published literature ". Food Chem. Toxicol. 40 (10): 1335-73. 43. Jens Rirk T.Auridsen (1976). " Food emulsifiers: Surface activity, edibility, manufacture, composition, and application ". Journal of the American Oil Chemists' Society 53 (6): 400-407. 44. Ballmann C, Mueller BW. Stimulating effect of cetosteaeyl alcohol and glyceryl monostearate as co-emulsifiers is hydrocarbon-ene 0 / W glyceride creams. Pharm Dev Technol. 2008; 13 (5): 433-45. 45. Akoh, Casimir C. (2006). Handbook of Functional Lipids. Washington, DC: Taylor & Francis. 46. http://www.drugs.com/sfx/vaseline-dermatology-fonnula-side-efFects.html, 08.07.2015. 47. W. Sterry, R. Paus, W, Burgdorf; Dermatology, Stuttgart [etc.]: Thieme, 2006, p. 586. 48. Ullmann's Encyclopedia of Industrial Chemistry. Copyright © 1999-2014 by John Wiley and Sons, Inc.
Claims (2)
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-15-90A LV15082B (en) | 2015-08-24 | 2015-08-24 | Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients |
PCT/LV2015/000006 WO2017034384A1 (en) | 2015-08-24 | 2015-08-25 | Epidermal lipid barrier restoring cream for facial skin, neck and decollete area for metabolic syndrome patients |
EP15902371.2A EP3439616A4 (en) | 2015-08-24 | 2015-08-25 | Epidermal lipid barrier restoring cream for facial skin, neck and decollete area for metabolic syndrome patients |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LVP-15-90A LV15082B (en) | 2015-08-24 | 2015-08-24 | Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients |
Publications (2)
Publication Number | Publication Date |
---|---|
LV15082A true LV15082A (en) | 2015-12-20 |
LV15082B LV15082B (en) | 2016-04-20 |
Family
ID=54846286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LVP-15-90A LV15082B (en) | 2015-08-24 | 2015-08-24 | Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP3439616A4 (en) |
LV (1) | LV15082B (en) |
WO (1) | WO2017034384A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6992057B2 (en) | 2016-06-10 | 2022-01-13 | クラリティ コスメティックス インコーポレイテッド | Non-acne-forming hair and scalp care products and how to use them |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3879470D1 (en) * | 1988-04-08 | 1993-04-22 | Stada Arzneimittel Ag | AMBIPHILE CREAM. |
US6630442B1 (en) * | 1997-01-10 | 2003-10-07 | Theodore Hersh | Reparatives for chemosurgery and laser (thermal) therapy |
WO2001017484A2 (en) * | 1999-09-07 | 2001-03-15 | D.T.R. Dermal Therapy Research Inc. | Topical urea composition |
-
2015
- 2015-08-24 LV LVP-15-90A patent/LV15082B/en unknown
- 2015-08-25 EP EP15902371.2A patent/EP3439616A4/en not_active Withdrawn
- 2015-08-25 WO PCT/LV2015/000006 patent/WO2017034384A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2017034384A1 (en) | 2017-03-02 |
EP3439616A4 (en) | 2020-03-04 |
EP3439616A1 (en) | 2019-02-13 |
LV15082B (en) | 2016-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2907495C (en) | Antioxidant compositions and methods of using the same | |
Wan et al. | Moisturizing different racial skin types | |
US20240197677A1 (en) | Putrescine slow-release topical formulations | |
KR20190101948A (en) | Composition for prevention or treatment of inflammatory skin diseases or severe pruritus comprising the aqueous solubilized ursodeoxycholic acid | |
Altuntaş et al. | Anti-aging potential of a cream containing herbal oils and honey: Formulation and in vivo evaluation of effectiveness using non-invasive biophysical techniques | |
AU2002318699B2 (en) | Cream for treatment of skin injured by the sun | |
Piccioni et al. | Improving skin aging, skin hydration and sensitive skin with four specific skin care products: results from a single-centre, observational, prospective study | |
AU2002318699A1 (en) | Cream for treatment of skin injured by the sun | |
Mehlich et al. | Acidification of the skin and maintenance of the physiological skin pH value by buffered skin care products formulated around pH 4 | |
LV15082A (en) | Cream for restoring epidermal lipid barrier of the facial skin, neck and decollette area in metabolic syndrome patients | |
US7306810B1 (en) | Skin cream | |
US20230000759A1 (en) | Ppar agonist complex and methods of use | |
WO2020201377A1 (en) | Cream for treatment of skin injured by the sun | |
JP4488933B2 (en) | Wrinkle improving agent and external composition for skin | |
KR100574850B1 (en) | Skin care composition containing synthetic palmitoyl pentapeptide | |
Kyi | A Split-face Double-blind Randomized Placebo-controlled Trial of the Efficacy of Kakadu Plum Extract for Reduction of Periorbital Wrinkles | |
Natasia et al. | Test the Potential of Macadamia Nut Oil (Macadamia F. Muell) as Sunscreen in Cream Preparations in Vitro | |
Clarys et al. | 27 New Trends in Antiaging Cosmetic Ingredients and Treatments: An Overview | |
Somwanshi et al. | Cosmetic Science | |
WO2023247838A1 (en) | Cosmetic or dermatological composition comprising polylysine dendrimers and use thereof | |
KR100355953B1 (en) | Skin Care Composition Containing Ursolic Acid and Synthetic Palmitoyl Pentapeptide | |
CN118526430A (en) | A compact anti-aging essential oil containing camellia seed oil extract and its preparation method | |
BRPI1107447A2 (en) | Cosmetic makeup, skin care kit, method for treating oily or mixed skin or acne skin | |
UHODA et al. | DRY SKIN IN DIABETIC PATIENTS | |
Botha | The stabilising effect of met [h] ylsulfonylmethane (MSM) on urea containing formulations |